Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease

Menopause

Volumn 15, Issue 6, 2008, Pages 1060-1064

  Yeboah, Joseph ^a   Klein, Karen ^a   Brosnihan, Bridget ^a   Reboussin, David ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cell adhesion molecules; Coronary artery disease; Hormone therapy; Postmenopausal women

Indexed keywords

CELL ADHESION MOLECULE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; MEDROXYPROGESTERONE ACETATE;

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; BLOOD; ESTROGEN THERAPY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY;

AGED; CORONARY ARTERY DISEASE; E-SELECTIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 63349109543     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31816d8171     Document Type: Article

References (42)

1. Maas AHEM, van der Graaf Y, van der Schouw YT, Grobbee DE. HRT and heart disease: problems and prospects. Maturitas 2004;47:255-258.
2. Maas AHEM, van der Schouw YT, Grobbee DE, van der Graaf Y. "Rise and fall" of hormone therapy in postmenopausal women with cardiovascular disease. Menopause 2004;11:228-235.
3. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997;20:426-432.
4. Allison MA, Manson JE. Observational studies and clinical trials of menopausal hormone therapy: can they both be right? Menopause 2006;13:1-3.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
7. Hulley S, Grady D, Vittinghoff E, et al. Hormone replacement therapy for secondary prevention of coronary heart disease [Letter]. JAMA 1999;281:797.
8. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women - the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
9. Wassertheil Smoller S, Hendrix S, Heiss G, Limacher M. Effect of estrogen plus progestin on stroke in the women's health initiative. Stroke 2003;34:244.
10. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
11. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
13. Manson JE, Allison MA, Roussow JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
14. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
15. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
16. Lim HS, Chong AY, Freestone B, Blann AD, Lip GY. The effect of multifactorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus. Implications for atherosclerotic vascular disease. Diabet Med 2005;22:249-255.
17. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6 and tissue factor in diabetes mellitus: relationship of cardiovascular disease and risk factor interaction. Circulation 2004;109:2524-2528.
18. Demerath E, Towne B, Blangero J, Siervogel RM. The relationship of soluble ICAM-I, VCAM-I, P-selectin, E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001;28:664-678.
19. Eschen O, Christensen JH, Toft E, Schmidt EB. Soluble adhesion molecules and marine n-3 fatty acids in patients referred for coronary angiography. Atherosclerosis 2005;180:327-331.
20. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients and with coronary artery disease. Circulation 2001;104:1336-1342.
21. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:4219-4225.
22. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-1802.
23. Sbarouni E, Kroupis C, Kyriakida ZS, Komavilou K, Kremastinos DT. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. Eur Heart J 2000;25:975-980.
24. Chou ET, Schulman SP, Thiemann DR, Sohn RH, Bellantoni MF, Rade JJ. Effects of short term estrogen with and without progesterone therapy on circulating markers of endothelial activation and injury in postmenopausal women with unstable angina pectoris. Am J Cardiol 2003;91:1240-1242.
25. Herrington DM, Reboussin DM, Klein KP, et al. The Estrogen Replacement and Atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort. Control Clin Trials 2000;21:257-285.
26. Scarabin P, Alhene-Gelas M, Plu-Bureau O, Plu-Bureau G. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women. A randomized controlled trial. Thromb Haemost 1999;81:673-675.
27. Herrington DM, Brosnihan B, Pusser B, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-4222.
28. Koh K, Bui M, Mincemoyer R, Cannon R. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal women. Am J Cardiol 1997;80:1505-1507.
29. Koh K, Jin D, Yang S, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-1966.
30. Lamon-Fava S, Posfai B, Schaefer EJ. Effects of hormone replacement therapy on C-reactive protein and cell adhesion molecules in postmenopausal women. Am J Cardiol 2003;91:252-254.
31. Salpeter SR, Walsh JM, Orniston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-554.
32. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
33. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
34. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
35. Seljeflot I, Tonstad S, Hjerman I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002;162:176-185.
36. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004;44:335-339.
37. Ferrario CM, Strawn WB. Role of renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-128.
38. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007;153:439-444.
39. Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005;179:193-200.
40. McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Clin Endocrinol (Oxf) 1996;45:435-441.
41. Guzic-Salobir B, Keber I, Seljeflot I, et al. Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med 2001;250:508-515.
42. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries in premenopausal women. Circulation 1994;89:1501-1510.